title: Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies.
abstract: BACKGROUND
  We conducted a follow-on study to a phase I randomized, controlled trial conducted in Cuba, 2012, to assess the persistence of poliovirus antibodies at 21-22 months following booster dose of Sabin-IPV compared to Salk-IPV in adults who had received multiple doses of oral poliovirus vaccine (OPV) during childhood.
  
  
  METHODS
  In 2012, 60 healthy adult males aged 19-23 were randomized to receive one booster dose, of either Sabin-inactivated poliovirus vaccine (Sabin-IPV), adjuvanted Sabin-IPV (aSabin-IPV), or conventional Salk-IPV. In the original study, blood was collected at days 0 (before) and 28 (after vaccination), respectively. In this study, an additional blood sample was collected 21-22 months after vaccination, and tested for neutralizing antibodies to Sabin poliovirus types 1, 2 and 3.
  
  
  RESULTS
  We collected sera from 59/60 (98.3%) subjects; 59/59 (100%) remained seropositive to all poliovirus types, 21-22 months after vaccination. The decay curves were very similar among the study groups. Between day 28 and 21-22 months, there was a reduction of ⩾87.4% in median antibody levels for all poliovirus types in all study groups, with no significant differences between the study groups.
  
  
  CONCLUSIONS
  The decay of poliovirus antibodies over a 21-22-month period was similar regardless of the type of booster vaccine used, suggesting the scientific data of Salk IPV long-term persistence and decay may be broadly applicable to Sabin IPV.
authors.affiliation: Institute Pedro Kouri, Havana, Cuba.
authors.forename: Sonia
authors.initials: S
authors.lastname: Resik
authors.affiliation: Provincial Health Office, Camagüey, Cuba.
authors.forename: Alina
authors.initials: A
authors.lastname: Tejeda
authors.affiliation: Institute Pedro Kouri, Havana, Cuba.
authors.forename: Magile
authors.initials: M
authors.lastname: Fonseca
authors.affiliation: The World Health Organization, Geneva, Switzerland.
authors.forename: Carolyn
authors.initials: C
authors.lastname: Sein
authors.affiliation: Institute Pedro Kouri, Havana, Cuba.
authors.forename: Lai Heng
authors.initials: LH
authors.lastname: Hung
authors.affiliation: Institute Pedro Kouri, Havana, Cuba.
authors.forename: Yenisleidys
authors.initials: Y
authors.lastname: Martinez
authors.affiliation: Institute Pedro Kouri, Havana, Cuba.
authors.forename: Manuel
authors.initials: M
authors.lastname: Diaz
authors.affiliation: The World Health Organization, Geneva, Switzerland.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Okayasu
authors.affiliation: The World Health Organization, Geneva, Switzerland.
authors.forename: Roland W
authors.initials: RW
authors.lastname: Sutter
keywords: Adjuvant; Aluminum hydroxide; Duration of antibodies; Inactivated poliovirus vaccine; Phase I trial; Sabin strains